Human Gene Therapy

3.0(top 20%)

impact factor

4.7K(top 5%)

papers

210.6K(top 2%)

citations

173(top 2%)

h-index

3.3(top 10%)

impact factor

5.7K

all documents

220.0K

doc citations

244(top 2%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	High Levels of Foreign Gene Expression in Hepatocytes after Tail Vein Injections of Naked Plasmid DNA	Human Gene Therapy	1999	912
2	Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial	Human Gene Therapy	2008	880
3	Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors	Human Gene Therapy	2010	776
4	Episomal Vectors Rapidly and Stably Produce High-Titer Recombinant Retrovirus	Human Gene Therapy	1996	689
5	A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme	Human Gene Therapy	2000	648
6	Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors	Human Gene Therapy	1998	641
7	Activation of the Complement System by Synthetic DNA Complexes: A Potential Barrier for Intravenous Gene Delivery	Human Gene Therapy	1996	572
8	Nonviral Vectors in the New Millennium: Delivery Barriers in Gene Transfer	Human Gene Therapy	2001	550
9	Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN	Human Gene Therapy	2018	543
10	A Powerful Nonviral Vector for In Vivo Gene Transfer into the Adult Mammalian Brain: Polyethylenimine	Human Gene Therapy	1996	518
11	Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors	Human Gene Therapy	1996	493
12	Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors FollowingIn VivoAdministration	Human Gene Therapy	1997	480
13	Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus	Human Gene Therapy	1996	476
14	High-Level Transduction and Gene Expression in Hematopoietic Repopulating Cells Using a Human Imunodeficiency Virus Type 1-Based Lentiviral Vector Containing an Internal Spleen Focus Forming Virus Promoter	Human Gene Therapy	2002	457
15	Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products	Human Gene Therapy	1995	455
16	Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung	Human Gene Therapy	1996	453
17	New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses	Human Gene Therapy	1998	445
18	Nomenclature for Synthetic Gene Delivery Systems	Human Gene Therapy	1997	444
19	Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo	Human Gene Therapy	1999	440
20	Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice	Human Gene Therapy	1993	438
21	In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene Therapy	Human Gene Therapy	1993	421
22	Retrovirus Packaging Cells	Human Gene Therapy	1990	411
23	Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir. National Institutes of Health	Human Gene Therapy	1993	410
24	Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors	Human Gene Therapy	2002	409
25	Improved Methods of Retroviral Vector Transduction and Production for Gene Therapy	Human Gene Therapy	1994	396
26	PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo	Human Gene Therapy	1999	390
27	Direct Gene Transfer into Skeletal MuscleIn Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression	Human Gene Therapy	1993	389
28	Systematic Determination of the Packaging Limit of Lentiviral Vectors	Human Gene Therapy	2001	380
29	Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers	Human Gene Therapy	2005	376
30	The Innate Immune Response to Adenovirus Vectors	Human Gene Therapy	2004	371
31	Characterization of Vectors for Gene Therapy Formed by Self-Assembly of DNA with Synthetic Block Co-Polymers	Human Gene Therapy	1996	370
32	Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA	Human Gene Therapy	2008	366
33	Bone Marrow Mesenchymal Stem Cells: Historical Overview and Concepts	Human Gene Therapy	2010	350
34	Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector	Human Gene Therapy	1990	346
35	Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Toxicity Study	Human Gene Therapy	1993	338
36	A Pilot Study ofIn VivoLiver-Directed Gene Transfer with an Adenoviral Vector in Partial Ornithine Transcarbamylase Deficiency	Human Gene Therapy	2002	337
37	Adenoviral Vector-Delivered Pigment Epithelium-Derived Factor for Neovascular Age-Related Macular Degeneration: Results of a Phase I Clinical Trial	Human Gene Therapy	2006	336
38	Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors	Human Gene Therapy	2006	335
39	An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal Muscle	Human Gene Therapy	1996	333
40	Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors	Human Gene Therapy	2005	333
41	Efficient Construction of a Recombinant Adenovirus Vector by an ImprovedIn VitroLigation Method	Human Gene Therapy	1998	329
42	Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma	Human Gene Therapy	1998	328
43	Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy	Human Gene Therapy	1993	327
44	Ultrasound-Mediated Transfection of Mammalian Cells	Human Gene Therapy	1996	327
45	Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses	Human Gene Therapy	1999	312
46	The Regulation of Differentiation in Mesenchymal Stem Cells	Human Gene Therapy	2010	312
47	A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy	Human Gene Therapy	1998	305
48	HumanRPE65Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year	Human Gene Therapy	2009	305
49	Promoter Attenuation in Gene Therapy: Interferon-γand Tumor Necrosis Factor-αInhibit Transgene Expression	Human Gene Therapy	1997	302
50	In Vivo Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic Fibrosis	Human Gene Therapy	1995	301

Scientometrics

Overviews

Citing Bodies

Human Gene Therapy

Top Articles